MDMA and Psilocybin are supplied to authorized clinics in regulated markets.
Supply is currently focused on Australia, with additional jurisdictions supported as access programs develop.
Reimbursement is handled at the clinic level within regulated programs. Optimi supplies products to authorized providers operating within those frameworks.
